M-701 is under clinical development by Wuhan YZY Biopharma and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase III drugs for Ovarian Cancer have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how M-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

M-701 overview

M-701 is under development for the treatment of malignant ascites caused by colorectal, ovarian, gastric and liver cancer and malignant pleural effusion caused by non-small cell lung cancer and solid tumor. The drug candidate is a recombinant human-mouse chimeric bi-specific antibody. It is administered through parenteral, intraperitoneal and intrathoracic route. It acts by targeting cells expressing epithelial cell adhesion molecule (EpCAM) and CD3.

Wuhan YZY Biopharma overview

Wuhan YZY Biopharma (YZY Biopharma) operates as a biotechnology company that develops medicines for cancer treatment. The company’s product pipeline include Y101D- PD-L1×TGF-ß is fot the treatment of bispecific antibody, Y150-CD38×CD3 is for specific antibody, Y2019 – RBD dimer subunit SARS-CoV-2 vaccine, M802 – HER2×CD3 bispecific antibody, Y400- VEGFxANG2 is for bispecific antibody, M701- relapsed or refractory multiple myeloma, Y101D is for the treatment of colorectal cancer, small cell lung cancer among others. It operates through its research and development lab, process development lab, analytical and quality center and a cGMP clinical production facility. YZY Biopharma is headquartered in Wuhan, Hubei, China.

For a complete picture of M-701’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.